The Appraisal - Does a charity have a role in biotech and pharma innovation? - Cancer Research UK

In this new podcast series, Executive Director of Research & Innovation at Cancer Research UK and CEO of Cancer Research Horizons, Dr Iain Foulkes brings you crisp insight and analysis from the sharp end of research leadership.

This entry is part 2 of 3 in the series The Appraisal with Dr Iain Foulkes

A recent report from Deloitte has shed new light on the staggering cost of developing new drugs – an expense that now exceeds $2 billion per therapy on average. It’s a cost only matched by the huge risk in undertaking the research and development needed to get a drug or intervention to market. So, is the ‘innovation economy’ of drug discovery sustainable? What can – perhaps should – be done about this? And does a charity like CRUK have a role here? Time to get some perspective on all this from Iain…

Some useful links:

Cancer Research Horizons is CRUK’s innovation engine built to complement it’s network of researchers. They take innovations from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients.

The report from Deloitte showing the cost of developing new drugs – an expense that now exceeds $2 billion per therapy on average.

FDA Commissioner Rob Califf says drug prices are too high.

Cancer News

The Appraisal – Does a charity have a role in biotech and pharma innovation?

Some useful links:

Highlighted content

More like this

Start-up – forging your own path

Latest winner in our Research is Beautiful campaign

Cancer Research Matters - Entrepreneurial deep dive